AAV with CMV promoter driven CreERT2

This AAV expresses CreERT2 driven by an ubiquitous CMV promoter.

This roughly 0.6 Kb promoter is the commonly used human cytomegalovirus (CMV) immediate-early promoter/enhancer (CMV/IE).

A mutated form of estrogen ligand-binding domain (ERT2) that binds to synthetic antagonists (such as tamoxifen or its derivative 4-hydroxy-tamoxifen) but not to circulating estrogen, was fused to the Cre recombinase (Cre) to create CreERT2 (also known as "inducible Cre"). When tamoxifen binds to CreERT2, it induces a conformational change of CreERT2, leading to its nuclear translocation, followed by Cre/Lox-mediated recombination.